Human umbilical cord mesenchymal stem cells improve the reserve function of perimenopausal ovary via a paracrine mechanism

Jia Li1,2, QiuXian Mao2, JingJun He3, HaoQing She4, Zhi Zhang5* and ChunYan Yin2*

Abstract

Background: Human umbilical cord mesenchymal stem cells (hUCMSCs) are a type of pluripotent stem cell which are isolated from the umbilical cord of newborns. hUCMSCs have great therapeutic potential. We designed this experimental study in order to investigate whether the transplantation of hUCMSCs can improve the ovarian reserve function of perimenopausal rats and delay ovarian senescence.

Method: We selected naturally aging rats confirmed by vaginal smears as models of perimenopausal rats, divided into the control group and the treatment group, and selected young fertile female rats as normal controls. hUCMSCs were transplanted into rats of the treatment group through tail veins. Enzyme-linked immunosorbent assay (ELISA) detected serum levels of sex hormones, H&E staining showed ovarian tissue structure and allowed follicle counting, immunohistochemistry and western blot analysis revealed ovarian expression of hepatocyte growth factor (HGF), vascular endothelial cell growth factor (VEGF), and insulin-like growth factor-1 (IGF-1), polymerase chain reaction (PCR) and western blot analysis revealed hUCMSCs expression of HGF, VEGF, and IGF-1.

Results: At time points of 14, 21, and 28 days after hUCMSCs transplantation, estradiol (E₂) and anti-Müllerian hormone (AMH) increased while follicle-stimulating hormone (FSH) decreased; ovarian structure improved and follicle number increased; ovarian expression of HGF, VEGF, and IGF-1 protein elevated significantly. Meanwhile, PCR and western blot analysis indicated hUCMSCs have the capacity of secreting HGF, VEGF, and IGF-1 cytokines.

Conclusions: Our results suggest that hUCMSCs can promote ovarian expression of HGF, VEGF, and IGF-1 through secreting those cytokines, resulting in improving ovarian reserve function and withstanding ovarian senescence.

Keywords: hUCMSCs, Perimenopausal, Ovarian reserve function, HGF, VEGF, IGF-1, Paracrine

Background

Menopause is the permanent termination of menstruation because of loss of ovarian follicular activity. Perimenopause means the coming of menopause, which manifests itself as menstrual irregularity and vasomotor symptoms, it ends in the 12 months after the final menstrual period [1]. Most women experience perimenopause classically between the ages of 45 and 55 years [2].

Perimenopause can last for several years or even decades, and brings many perimenopausal symptoms such as hot flushes, vaginal atrophy, osteoporosis, depression, etc. [3, 4]. Currently, hormone replacement therapy (HRT), symptomatic supporting treatment, and treatment with phytoestrogens or herbal remedies are the three main treatments of perimenopausal symptoms. However, HRT may have a long-term effect on increasing the risk of breast cancer, endometrial cancer, and ovarian cancer; symptomatic supporting treatment cures the symptoms, not the disease; and treatment with phytoestrogens or herbal remedies lacks data on the mechanism and long-term safety [1, 4]. The delay of
childbearing as an important social change has led to an increasing number of women desiring late menopause, and the improvement of the quality of life means women want to avoid the trouble of perimenopausal symptoms and to slow down the rapidity of ovarian aging. In addition, follicles have limited numbers. Several million non-growing follicles (NGFs) are established by the ovary at around 5 months of gestational age, then decline to approximately 1000 when the menopause starts, and are finally exhausted through atresia and apoptosis after 12–14 years of menopause [5, 6]. Therefore, how to make the best use of NGFs, delay ovarian senescence, and cure perimenopausal syndrome fundamentally are a serious problem in today’s society.

Human mesenchymal stem cells (MSCs) have attracted great interest recently, due to their huge therapeutic potential. Human umbilical cord mesenchymal stem cells (hUCMSCs) are obtained directly from the Wharton’s jelly of a human umbilical cord, and are also called human Wharton’s jelly mesenchymal stem cells (WJ-MSCs). Fewer ethical issues, being obtained painlessly from abandoned umbilical cord, and being hypoimmunogenic are the prominent advantages of hUCMSCs compared to other sources of MSCs [7]. The ability to modulate immune responses makes hUCMSCs an important stem cell source for allogeneic transplantation therapy without immunological rejection [8]. Troyer and Weiss [9] concluded that there was no evidence for direct immunological rejection of undifferentiated hUCMSCs in vivo and they would be accepted well in allogeneic transplantation. Besides, Gong et al. [10] discovered that there were no signs of immunologic response and no evidence in the dosage escalation and frequencies of hUCMSCs used in patients. Furthermore, hUCMSCs have multipotent stem cell characteristics, which can differentiate into multiple lineages under different differentiation conditions [11]. Some studies also showed [12, 13] that hUCMSCs differentiated into oocyte-like structures and expressed both mRNA and protein of germ cell-specific markers. hUCMSCs increased the proliferation of damaged human endometrial stromal cells (ESCs) and decreased the apoptosis percentage significantly when cultured with them. Yang et al. [14] suggested that hUCMSCs may restore endometrial damage through secreting vascular endothelial growth factor (VEGF) and anti-apoptosis. Zhu et al. [15] confirmed that hUCMSCs transplantation could restore ovaries damaged by chemotherapy in rats. This experiment was lately verified by Song et al. [16]. They all proposed that the improved ovarian function in premature ovarian failure (POF) rat model was more likely due to the cytokines produced by hUCMSCs via a paracrine mechanism rather than directly differentiating to germ cells.

Early follicle-stimulating hormone (FSH) was a main endocrine feature of perimenopause, reported by Sherman and Korenman in 1975 for the first time [17], and has been used since the 1990s as a biomarker of reproductive potential [18]. Mean FSH levels between the earliest menopausal phase of every definition showed statistically significant differences, and serum estradiol (E2) levels decrease and FSH levels increase with growing age in midlife women [19]. Therefore, Gracia et al. [20] suggested that delicate changes in blood may be helpful in recognizing the earliest hormonal changes during the transition to menopause. However, the increase of FSH levels only happens around 10 years before the menopause in which infertility perhaps starts. Thus, a markedly raised FSH is considered a relatively late predictor for menopausal transition [21]. Anti-Müllerian hormone (AMH), as a member of the transforming growth factor beta (TGF-β) family, can affect the transition from NGFs to growing follicles. Hence it is viewed currently as the best available predictor of ovarian reserve [22]. AMH levels remain relatively stable over the menstrual cycle; therefore, measurement does not need to be conducted on a specific cycle day. In such a way, AMH has the advantage over FSH [18]. Individual AMH serum level reflects the size of the antral follicles pool, representing the quantity of NGFs accurately [23]. Since AMH production decrease is in accord with the age-related decline in the number of antral follicles, AMH levels can be used as a label for ovarian aging [24–26].

Based on the precedents discussed above, we designed this experiment to investigate the therapeutic potential of hUCMSCs using perimenopausal rats. We established the perimenopausal sample by selecting naturally aging rats, confirmed by vaginal smears and the level of serum hormone. The sample is in accordance with the status of perimenopausal women. In addition, we chose serum level of E2, AMH, and FSH as the evaluation index of ovarian reserve function. Our study aimed to identify the potential of hUCMSCs in perimenopausal treatment and the mechanism involved.

Methods

Animals

The naturally aging female Sprague-Dawley rats (SPF class, weight 410–450 g, 12–14 months old) and young female Sprague-Dawley rats with fertility (SPF class, weight 280–320 g, 3–5 months old) were provided by Guangdong Medical Laboratory Animal Center (Foshan City, China). They were bred at a temperature of 30 ± 2 °C with a 12-hour light/dark cycle. Vaginal smears of rats were taken to determine estrous cycle at 11:00 am daily. Only aging rats with disorganized estrous cycles and young rats with normal estrous cycles were chosen [27, 28]. Before the
experiment, 1 ml of blood was gathered from each rat’s orbital during dioestrus. We centrifuged blood samples for 10 minutes at 2000 rpm after 45 minutes’ standing and reserved the upper serum at -80 °C. Initial levels of rat E2, FSH, and AMH were accessed for each serum sample. Aging rats were distributed into the control group and the treatment group (n = 15 per group) randomly. Young rats were set as the normal control group (n = 15).

Identification of hUCMSCs phenotype
The P1 generation cell lines of hUCMSCs were obtained from ChongQing HuaYa Stemcell Technology Corporation (ChongQing, China). hUCMSCs were isolated from human umbilical cords of newborns. Maternal blood passed the etiological examination, proving that they were not infected by treponema pallidum, hepatitis B virus, and human immunodeficiency virus. Flow cytometry was used to identify the phenotype of hUCMSCs. CD73(e-Bioscience, Inc., San Diego, CA, USA, 12-0739-41), CD90 (eBioscience, 11-0909-41), CD105 (eBioscience, 12-1057-41), CD14 (eBioscience, 11-0149-41), CD34 (eBioscience, 12-0349-41), CD45 (eBioscience, 11-0459-41), CD79a (eBioscience, 12-0792-41) and HLA-DR (eBioscience, 11-9952-41) monoclonal antibodies were used for detection. Mouse IgG monoclonal antibody was used as negative control. Cells at a concentration of 2 × 10^6 cells/ml were incubated with 5 ul antibodies (for each) at 4 °C for 30 minutes and were analyzed by flow cytometer (Beckman Coulter, Brea, CA, USA, MoFlo Astrios EQ).

Treatment
hUCMSCs were cultured in complete medium (DEME/F12 with 10% FBS and 1% penicillin-streptomycin) until they fulfilled the quantity. And then the P3 generation of hUCMSCs was cultured in culture dishes until they grew to 90% confluence. After that, culture media were abandoned and cells were washed in PBS three times. The total RNA of the cells was extracted using E.Z.N.A.Total RNA Kit I (Omega Bio-tech, Inc., Norcross, GA, USA, R6834-01). Before RNA was transcribed, DNase I (Beyotime, Shanghai, China, D7076) had been added to remove the genome DNA. Ultraviolet spectrophotometry was used to determine the concentration of total RNA. RNA was transcribed reservedly to cDNA using PrimeScript™ 1st Strand cDNA Synthesis Kit (Takara Bio Inc., Kyoto, Japan, 6110A), and cDNA was amplified by Premix Taq™ version 2.0 plus dye kit (Takara Bio USA Inc., Mountain View, CA, USA, RR901Q). Distilled water was used to replace cDNA as the blank control of quality when amplified. Human hepatocyte growth factor (HGF), VEGF and insulin-like growth factor-1 (IGF-1) primer (both from Sangon Biotech, Shanghai, China) was designed according to GeneBank, primer sequences are as below.

**PCR analysis hUCMSCs HGF, VEGF, and IGF-1 mRNA expression**
The P3 generation of hUCMSCs was cultured in culture dishes until they grew to 90% confluence. After that, culture media were abandoned and cells were washed in PBS three times. The total RNA of the cells was extracted using E.Z.N.A.Total RNA Kit I (Omega Bio-tech, Inc., Norcross, GA, USA, R6834-01). Before RNA was transcribed, DNase I (Beyotime, Shanghai, China, D7076) had been added to remove the genome DNA. Ultraviolet spectrophotometry was used to determine the concentration of total RNA. RNA was transcribed reservedly to cDNA using PrimeScript™ 1st Strand cDNA Synthesis Kit (Takara Bio Inc., Kyoto, Japan, 6110A), and cDNA was amplified by Premix Taq™ version 2.0 plus dye kit (Takara Bio USA Inc., Mountain View, CA, USA, RR901Q). Distilled water was used to replace cDNA as the blank control of quality when amplified. Human hepatocyte growth factor (HGF), VEGF and insulin-like growth factor-1 (IGF-1) primer (both from Sangon Biotech, Shanghai, China) was designed according to GeneBank, primer sequences are as below.

**PCR analysis hUCMSCs HGF, VEGF, and IGF-1 mRNA expression**
The P3 generation of hUCMSCs was cultured in culture dishes until they grew to 90% confluence. After that, culture media were abandoned and cells were washed in PBS three times. The total RNA of the cells was extracted using E.Z.N.A.Total RNA Kit I (Omega Bio-tech, Inc., Norcross, GA, USA, R6834-01). Before RNA was transcribed, DNase I (Beyotime, Shanghai, China, D7076) had been added to remove the genome DNA. Ultraviolet spectrophotometry was used to determine the concentration of total RNA. RNA was transcribed reservedly to cDNA using PrimeScript™ 1st Strand cDNA Synthesis Kit (Takara Bio Inc., Kyoto, Japan, 6110A), and cDNA was amplified by Premix Taq™ version 2.0 plus dye kit (Takara Bio USA Inc., Mountain View, CA, USA, RR901Q). Distilled water was used to replace cDNA as the blank control of quality when amplified. Human hepatocyte growth factor (HGF), VEGF and insulin-like growth factor-1 (IGF-1) primer (both from Sangon Biotech, Shanghai, China) was designed according to GeneBank, primer sequences are as below. HGF: forward (5′-GCAATTAAAACATGGCCTGA-3′), reverse (5′-TGAGAATTGGAGGAGTAGC-3′), overall length is 269 bp; VEGF: forward (5′-GGGGAGGAGAAGAAGAAGAAGA-3′), reverse (5′-GAGGGTATGGCTCCAGCAGTC-3′), overall length is 315 bp; IGF-1: forward (5′-AGGGTATGGCTCCAGCAGTC-3′), reverse (5′-GAGGGTATGGCTCCAGCAGTC-3′), overall length is 106 bp. 5 ul purpose gene amplification product was taken for electrophoresis on 2% agarose gel. Observation under the gel imaging analysis system was conducted, with photographs taken.

**H&E staining showed ovarian tissue structure and allowed follicle counting**
Left ovaries were removed for fixation in 10% formalin to prepare the paraffin sections. Each section was 3 um thick. Sections were stained with hematoxylin and eosin (H&E) and observed under a light microscope. The number of follicles at different stages was counted according to definition. Primordial follicles were defined as an oocyte surrounded by a single fusiform granule cell. Primary follicles were an oocyte surrounded by a single layer of cuboidal granulosa cells. Secondary follicles were surrounded by six to eight layers of cuboidal granulosa cells, with no visible antrum. Antral possessed a clearly defined antral space [29].
Western blot analysis of hUCMSCs expression of HGF, VEGF, and IGF-1

The P3 generation of hUCMSCs was cultured in culture dishes until they grew to 90% confluence. After that, the culture media was abandoned and cells were washed in PBS three times. The total protein was extracted from the cells using a total protein extraction kit (Nanjing Keygen Biotech Co. Ltd, Nanjing, China, KGP250) and the protein content was measured by BCA protein quantitation assay kit (Keygen Biotech, KGP904). Protein was taken according to the quantitation for electrophoresis on 12% SDS-PAGE gel. We used 5% skimmed milk with TBST and closed PVDF membrane after transmembrane. The primary antibodies used HGF (1:1500 dilution; ab83760; Abcam, Cambridge, MA, USA), VEGF (1:1200 dilution; ab46154; Abcam), IGF-1 (1:600 dilution; ab176523; Abcam) for the reaction at 4 °C overnight. The second antibodies used HRP-conjugated Affinipure Go at Anti-Mouse IgG (H + L) or HRP-conjugated Affinipure Goat Anti-rabbit IgG (H + L) (1:8000 dilution; SA00001-1 or SA00001-2; Proteintech, Wuhan, China) for the reaction at room temperature for 1 hour. Chemiluminescence used the Tanon 5200 analysis system (Tanon Science & Technology Co Ltd., Shanghai, China).

Immunohistochemistry analysis of ovarian expression of HGF, VEGF, and IGF-1

The ovary sections were immunohistochemically stained for HGF, VEGF, and IGF-1 antibodies in order to explore the cytokine expression in ovaries after hUCMSCs transplantation. Antigen was retrieved by microwave antigen retrieval in sodium citrate buffer (pH6.0). Immunohistochemistry (IHC) assay used the S-P method (ZSGB-Bio, Beijing, China, SP-9000-D). The primary antibodies HGF (1:300 dilution; ab83760; Abcam), VEGF (1:300 dilution; ab46154; Abcam) and IGF-1 (1:50 dilution; ab176523; Abcam) were used for the reaction at 4 °C overnight. The primary antibody was replaced by PBS as the negative control. DAB kit (ZSGB-Bio, ZLI-9017) was used for staining. All sections were observed and semi-quantitatively analyzed under a light microscope by two pathologists independently. The immunoreactive score (IRS) is according to their staining intensity and positive range at high magnification (×400). Staining intensity was divided into four levels (negative, weak, intermediate, strong), and given 0–3 scores respectively. The positive range was divided into five levels and given 0–4 scores respectively according to the positive cells’ percentage of the microscopic view (0–10%, 11–25%, 26–50%, 51–75%, or 76–100%). Ten view-zones were chosen for each section, which avoided overlaps on observation.

Fig. 1 Flow cytometry analysis of phenotype characterization of hUCMSCs. Phenotype of CD73, CD90, CD105, CD14, CD34, CD45, CD79a and HLA-DR of hUCMSCs was detected by flow cytometry. Intensity ≥ 95% represented strong expression while ≤2% represented low or no expression.
The score of staining intensity multiplying the score of the positive range decides the score of a view zone and the average score of ten view zones determines the score of a staining section.

Western blot analysis of ovarian expression of HGF, VEGF, and IGF-1
Right ovaries were washed in saline and stored at -80 °C. Each ovary’s total protein was extracted for the expression of HGF, VEGF, and IGF-1 assay by western blotting. The experiment method was the same as the cells’ western blot assay method. The Tanon 5200 Chemiluminescence Imaging System was used to analyze image intensity. The standardization ratio of target protein intensity to GAPDH (1:8000 dilution; 3777R-100; BioVision, Inc., Milpitas, CA, USA) intensity was viewed as the reference index of expression quantity.

Statistical analysis
All data were analyzed using IBM Statistical Program for Social Sciences 20.0 (IBM Corp., Armonk, NY, USA). The results were shown as the mean ± standard deviation. Data from the same group at different time points and data from multiple groups at the same time point were analyzed by one-way ANOVA test. The contrast between two groups used Students’ t test. P values were considered significant when less than 0.05.

Results
Phenotype characterization of hUCMSCs
Flow cytometry test results showed that hUCMSCs express the specific markers of mesenchymal cell such as CD73, CD90, CD105 (≥95%) while they do not express CD14, CD34, CD45, CD79a and HLA-DR (≤2%) (Fig. 1).

Table 1 The number of primordial, primary, secondary, and antral follicles at 14 days after transplantation

| Group       | Primordial | Primary | Secondary | Antral |
|-------------|------------|---------|-----------|--------|
| Control     | 20.20 ± 2.86 | 7.00 ± 1.00 | 8.60 ± 2.07 | 1.40 ± 0.89 |
| Treatment   | 28.40 ± 4.15* | 13.80 ± 3.56* | 12.60 ± 3.91 | 3.80 ± 1.48* |
| Normal control | 34.60 ± 6.07* | 16.00 ± 5.05* | 14.40 ± 4.22* | 8.20 ± 1.79* |
| F value     | 12.562      | 8.423    | 3.535     | 28.774  |
| P value     | 0.001       | 0.005    | 0.062     | <0.001  |

Data are shown as mean ± SD. *(n = 5)*

*P < 0.05 vs. control group

Table 2 The number of primordial, primary, secondary, and antral follicles at 21 days after transplantation

| Group       | Primordial | Primary | Secondary | Antral |
|-------------|------------|---------|-----------|--------|
| Control     | 17.40 ± 2.70 | 7.60 ± 1.52 | 5.80 ± 1.30 | 2.00 ± 0.71 |
| Treatment   | 26.80 ± 2.77* | 12.00 ± 1.22* | 10.60 ± 2.70* | 4.60 ± 1.14* |
| Normal control | 33.00 ± 7.75* | 16.40 ± 4.62* | 14.60 ± 4.04* | 8.40 ± 1.67* |
| F value     | 12.339      | 11.570   | 11.510    | 33.783  |
| P value     | 0.001       | 0.002    | 0.002     | <0.001  |

Data are shown as mean ± SD. *(n = 5)*

*P < 0.05 vs. control group
hUCMSCs transplantation does not cause rats’ graft rejection

There was no difference between the three groups of rats in their mental status, diet, hair color, and activity after transplantation. Moreover, there were no deaths, bleeding, hemiplegia, convulsions, and other graft rejection reactions in the treatment group. This implies that hUCMSCs transplantation is safe for Sprague-Dawley rats.

hUCMSCs transplantation improves rats’ ovarian reserve function

Before hUCMSCs transplantation, rats’ serum E₂ and AMH level of the control group and the treatment group significantly decreased, while FSH increased compared to the normal control group. On the other hand...

Table 3 The number of primordial, primary, secondary, and antral follicles at 28 days after transplantation

| Group          | Primordial | Primary | Secondary | Antral |
|----------------|------------|---------|-----------|--------|
| Control        | 21.80 ± 7.22 | 8.80 ± 3.90 | 6.80 ± 1.64 | 2.80 ± 0.84 |
| Treatment      | 27.80 ± 2.77 | 13.80 ± 2.77* | 10.60 ± 1.82* | 5.00 ± 1.00* |
| Normal control | 35.00 ± 5.57* | 17.00 ± 3.74* | 15.20 ± 3.77* | 8.20 ± 1.92* |

F value 6.943 13.139 7.208 20.481

P value 0.010 0.001 0.009 <0.001

Data are shown as mean ± SD. (n = 5)

*P < 0.05 vs. control group

Fig. 3 H&E staining analysis of ovarian structures. a Control group. b Treatment group at 14 days after hUCMSCs transplantation. c Treatment group at 21 days after hUCMSCs transplantation. d Treatment group at 28 days after hUCMSCs transplantation. e Normal control group. Scale bar = 500 um
hand, there was no significant difference between the two perimenopausal groups. After hUCMSCs transplantation, however, rats’ serum E2 and AMH of the treatment group increased and FSH decreased. This tendency has clear differences compared with the control group (Fig. 2; \( P<0.05 \)), yet has no significant difference between each time period of 14, 21, and 28 days after hUCMSCs treatment. Rats’ sera hormone level of the normal control group has no change at each time point.

**hUCMSCs transplantation improves rats’ ovary structure and follicle counting**

Primordial, primary, secondary, and antral follicles were classified and counted according to the previous description and definition (Tables 1, 2, and 3). In the normal control group, histomorphology of normal ovaries were observed (Fig. 3e). Conversely, in the control group, we found that ovarian stromal showed densification, the number of follicles at different periods were decreased (Fig. 3a). Expectedly, in the treatment group, developmental condition of follicles tended to improve, the number of ovarian follicles was increased (Fig. 3b, c, d). The forms of rats’ ovarian tissue at different time points after transplantation were similar in the treatment group.

**hUCMSCs can secrete HGF, VEGF, and IGF-1**

Polymerase chain reaction (PCR) results suggested that hUCMSCs expressed HGF, VEGF, and IGF-1 mRNA (Fig. 4a). Meanwhile, western blot results suggested that
hUCMSCs expressed HGF, VEGF, and IGF-1 protein (Fig. 4b). Western blot results were in accordance with PCR results, proving that hUCMSCs can secrete HGF, VEGF, and IGF-1 cytokines.

**HGF, VEGF, and IGF-1 expression in rats’ ovaries were improved after hUCMSCs transplantation**

We found that HGF, VEGF, and IGF-1 were massively detected in rats’ ovarian granulosa cells, theca cells, and stromal cells through IHC. In addition, the expression of HGF, VEGF, and IGF-1 in the normal control group was frequently observed, while the control group showed a lower trend. After hUCMSCs transplantation, however, HGF, VEGF, and IGF-1 protein expression apparently rose compared to the control group (Fig. 5). The IRS of the three groups was statistically different (Tables 4, 5 and 6). This was later confirmed by western blot assay (Fig. 6). The standardization ratio of protein expression of HGF, VEGF, and IGF-1 in the treatment group and the normal control group significantly showed that ovarian expression of HGF, VEGF, and IGF-1 proteins of perimenopausal rats tended to be close to young rats after hUCMSCs treatment, compared to the control group.

**Discussion**

While many researchers focus attention on the treatment of POF rats using adipose-derived mesenchymal stem cells (A-MSCs) [30], bone marrow mesenchymal stem cells (BMSCs) [31], and hUCMSCs [15, 16], our study focuses on the treatment of perimenopausal rats using hUCMSCs. In our study, the serum level of E2 and AMH decreased while FSH increased when the perimenopausal group of rats was selected. After hUCMSCs transplantation, we detected the serum index of E2, AMH, and FSH again and observed ovary tissue structures. The results suggested that hUCMSCs transplantation improved ovarian reserve function of perimenopausal rats. Although hUCMSCs have the ability to differentiate into germ cells, modern theories tend to deem [15, 16] that hUCMSCs do not change to oocyte-like structures or cells in vivo. Additionally, hUCMSCs labelled with fluorochrome mainly concentrated on the ovarian stroma, not on the ovarian follicle.

Follicle development needs the support of the vascular network in the ovary, hence inadequate ovarian stroma vessels may lead to a decline of oocyte quality with aging [32]. The development of vascular networks in the theca cell layer of the follicle is induced by angiogenic cytokines. In the ovary, the angiogenic factors produced by granulosa cells help to maintain the vasculature and health of the dominant follicles [33, 34]. A research study reported [35] that increasing age along with the reduction of ovarian stromal blood flow is a relatively late phenomenon, occurring only in women aged ≥41 years. As for angiogenic cytokines, VEGF is an effective mitogen for vascular endothelium [36] and it also stimulates vascular permeability [37]. Improving VEGF expression during the follicular stage may be helpful in increasing ovarian angiogenesis and the number of predominant follicles doomed for ovulation [38–41]. Beyond that, VEGF is a powerful survival factor for ovarian granulosa cell apoptosis and ovarian follicular atresia [42, 43]. Apart from VEGF, HGF is an important element of the internal follicular environment that accelerates the viability of growing follicles and enhances the proliferation of ovarian surface epithelium in order to replenish the area damaged due to expulsion of the ovum during ovulation [44, 45]. HGF, expressed both in thecal cells and granulosa cells of rat ovaries, may play its function as a modulator of the mesenchymal-epithelial cell reciprocities between theca cells and granulosa by facilitating cell proliferation and steroid hormone production [46]. A complete HGF system also supports granulosa

**Table 4** Comparison of the IHC scores for HGF

| Group       | 14 d | 21 d | 28 d | F value | P value |
|-------------|------|------|------|---------|---------|
| Control     | 1.66 ± 0.29 | 1.66 ± 0.23 | 1.72 ± 0.33 | 0.073 | 0.930 |
| Treatment   | 2.92 ± 0.53 | 3.30 ± 0.42 | 3.10 ± 0.22 | 1.080 | 0.371 |
| Normal control | 3.04 ± 0.25 | 3.12 ± 0.16 | 3.12 ± 0.16 | 0.274 | 0.765 |
| F value     | 20.723 | 47.584 | 51.122 |       |       |
| P value     | <0.001 | <0.001 | <0.001 |       |       |

Data are shown as mean ± SD. (n = 5)

IHC immunohistochemistry, HGF hepatocyte growth factor

**Table 5** Comparison of the IHC scores for VEGF

| Group       | 14 d | 21 d | 28 d | F value | P value |
|-------------|------|------|------|---------|---------|
| Control     | 1.68 ± 0.36 | 1.82 ± 0.46 | 1.54 ± 0.26 | 0.722 | 0.506 |
| Treatment   | 2.90 ± 0.89 | 2.78 ± 0.45 | 3.02 ± 0.38 | 0.190 | 0.829 |
| Normal control | 3.06 ± 0.62 | 3.12 ± 0.54 | 2.98 ± 0.66 | 0.067 | 0.936 |
| F value     | 6.574 | 9.657 | 16.482 |       |       |
| P value     | <0.012 | <0.003 | <0.001 |       |       |

Data are shown as mean ± SD. (n = 5)

IHC immunohistochemistry, VEGF vascular endothelial cell growth factor

**Table 6** Comparison of the IHC scores for IGF-1

| Group       | 14 d | 21 d | 28 d | F value | P value |
|-------------|------|------|------|---------|---------|
| Control     | 1.50 ± 0.12 | 1.30 ± 0.12 | 1.16 ± 0.21 | 6.00 | 0.016 |
| Treatment   | 2.20 ± 0.45 | 2.12 ± 0.33 | 2.10 ± 0.20 | 0.118 | 0.890 |
| Normal control | 2.64 ± 0.30 | 2.66 ± 0.28 | 2.52 ± 0.24 | 0.377 | 0.694 |
| F value     | 15.840 | 34.312 | 51.957 |       |       |
| P value     | <0.001 | <0.001 | <0.001 |       |       |

Data are shown as mean ± SD. (n = 5)

IHC immunohistochemistry, IGF-1 insulin-like growth factor-1

*P < 0.05 vs. control group
cells growing via an anti-apoptotic effect [47]. Besides, as for other important cytokines in the ovary, IGF-1 is expressed in growing granulosa cells and healthy follicles, which cannot be detected in atretic follicles [48] and is necessary for the proliferation of granulosa cells at the early stage of folliculogenesis [49]. According to studies [50, 51], ovarian IGF-1 expression stimulates progesterone and estradiol production, and enhances granulosa cell FSH reactivity by improving FSH receptor expression. A study reported [52] that serum and follicular fluid levels of IGF-1 are decreased in reproductive aging women aged 40–45 years compared to young women aged 20–25 years. Thus, IGF-1 plays a crucial role in follicular development. In addition, a study suggested [16] that the amount of hUCMSCs in the rat ovarian tissue was basically constant without obvious proliferation for at least 8 weeks. This conforms to the results of our study; both serum hormone concentration and ovarian expression of HGF, VEGF, and IGF-1 protein remaining stable to 28 days after hUCMSCs transplantation.

hUCMSCs can secrete cytokines such as VEGF, HGF, and IGF-1. In addition, the ovarian expression of VEGF, HGF, and IGF-1 distinctly increased after hUCMSCs transplantation into perimenopausal rats via the tail vein. The results implied that hUCMSCs transplantation improved ovarian reserve function of perimenopausal rats through a paracrine mechanism.

**Conclusions**

Through this study we suggest that hUCMSCs may be localized to the ovarian stroma and secreted cytokines after transplantation, affecting ovaries via a paracrine mechanism persisting at least 28 days. We can consider that hUCMSCs have therapeutic effects for perimenopausal rats to improve ovarian reserve function via a paracrine mechanism. However, based on these results, the time should be extended to more than 28 days to understand the timeliness of the therapeutic effects of hUCMSCs transplantation. Furthermore, whether the fertility of perimenopausal rats could be recovered after hUCMSCs transplantation needs further observation and testing. We hope this study can provide a theoretical foundation for perimenopausal treatment.

**Abbreviations**

AMH: Anti-Müllerian hormone; A-MSCs: Adipose-derived mesenchymal stem cells; BMSCs: Bone marrow mesenchymal stem cells; E2: Estradiol; ELISA: Enzyme-linked immunosorbent assay; ESCs: Endometrial stromal cells; FSH: Follicle-stimulating hormone; H&E: Hematoxylin and eosin; HGF: Hepatocyte growth factor; HRT: Hormone replacement therapy; hUCMSCs: Human umbilical cord mesenchymal stem cells; IGF-1: Insulin-like growth factor-1; IHC: Immunohistochemistry; IRS: Immunoreactive score; MSCs: Human mesenchymal stem cells; NGF: Non-growing follicles;
This study was approved by the ethics committee of Guangdong No.2 Provincial People’s Hospital for their technical assistance.

Funding
This work was supported by the Medical Science and Technology Research Foundation of Guangdong Province (No. A2016497).

Availability of data and materials
Not applicable.

Authors’ contributions
JL contributed to the experimental operation, manuscript writing, and literature review. QXM was responsible for animal modeling. JJH and HQS contributed to the experimental operation, manuscript writing, and situ and in vitro surveys. Stem Cells. 2007;25:319–31.

Authors’ information
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Our investigation using experimental animals was conducted on the basis of the GuangDong Medical Laboratory Animal Center’s specific guidelines and standards. This study was approved by the ethics committee of Guangdong No.2 Provincial People’s Hospital (GDZH-QR-KJ-018).

Author details
1Department of Obstetrics and Gynecology, Graduate College, Guangdong Medical University, Zhanjiang, Guangdong 524023, China. 2Department of Obstetrics and Gynecology, Guangdong No.2 Provincial People’s Hospital, NO.466 Xixangdong Road, Guangzhou 510317, China. 3Department of Obstetrics and Gynecology, Medical College, NanHua University, Hengyang, Hunan 421001, China. 4Department of Laboratory Medicine, Guangdong No.2 Provincial People’s Hospital, NO.466 Xixangdong Road, Guangzhou 510317, China.

Received: 14 October 2016 Revised: 5 January 2017 Accepted: 18 February 2017 Published online: 09 March 2017

References
1. Rees M. Management of the menopause: integrated health-care pathway for the menopausal woman. Menopause Int. 2011;17:50–4.
2. Broderston J. Contraception meets HRT: seeking optimal management of the perimenopause. Brit J Gen Pract. 2015;65:e630–2.
3. Weber MT, Maki PM, McDermott MP. Cognition and mood in perimenopause: A systematic review and meta-analysis. J Steroid Biochem Mol Biol. 2014;142:980–9.
4. Ottmann O, Dören M, Windler E. Hormone therapy in perimenopause and postmenopause (HT). Arch Gynecol Obstet. 2011;284:343–55.
5. Richardson SJ, Senkav S, Nelson JF. Follicular depletion during the perimenopausal transition: evidence for accelerated loss and ultimate exhaustion. J Clin Endocrinol Metab. 1987;65:1231–7.
6. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod. 1992;7:1342–6.
7. Bongso A, Fong C. The therapeutic potential, challenges and future clinical directions of stem cells from the Wharton’s jelly of the human umbilical cord. Stem Cell Rev. 2013;9:226–40.
8. Fong C, Chak L, Biswas A, Tan J, Gauthaman K, Chan W, Bongso A. Human Wharton’s jelly stem cells have unique transcriptome profiles compared to human embryonic stem cells and other mesenchymal stem cells. Stem Cell Rev. 2011;7:1–16.
9. Troyer DL, Weiss ML. Concise review: Wharton’s jelly-derived cells are a primitive stromal cell population. Stem Cells. 2008;26:591–9.
10. Gong W, Han Z, Zhao H, Wang Y, Wang J, Zhong J, Wang B, Wang S, Wang Y, Sun L, Han Z. Banking human umbilical cord-derived mesenchymal stromal cells for clinical use. Cell Transplant. 2012;21:207–16.
11. Karahusseyinoglu S, Cinar O, Kilic E, Kara F, Akay GG, Demiralp DO, Tukan A, Uckun D, Can A. Biology of stem cells in human umbilical cord stromal in situ and in vitro surveys. Stem Cells. 2007;25:319–31.
12. Qiu P, Bai Y, Pan S, Li W, Liu W, Hua J. Gender depended potentiality of differentiation of human umbilical cord mesenchymal stem cells into oocyte-like cells in vitro. Cell Biochem Funct. 2013;31:365–73.
13. Huang P, Lin LM, Wu XY, Tang QL, Feng XY, Lin GY, Lin X, Wang HW, Huang TH, Ma L. Differentiation of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells into germ-like cells in vitro. J Cell Biochem. 2010;109:747–54.
14. Yang X, Zhang M, Zhang Y, Li W, Yang B. Mesenchymal stem cells derived from Wharton jelly of the human umbilical cord ameliorate damage to human endometrial stromal cells. Fertil Steril. 2011;96:1029–36.
15. Zhu SF, Hu HB, Xu HY, Fu XF, Peng DX, Su WY, He YL. Human umbilical cord mesenchymal cell transplantation restores damaged ovaries. J Cell Mol Med. 2015;19:2108–17.
16. Song D, Zhong Y, Qian C, Zou Q, Ou J, Shi Y, et al. Human umbilical cord mesenchymal stem cells therapy in cyclophosphamide-induced premature ovarian failure rat model. Biomed Res Int. 2016;2016:1–13.
17. Sherman BM, Koresnigan SG. Hormonal characteristics of the human menstrual cycle throughout reproductive life. J Clin Invest. 1975;55:699–706.
18. Steiner A. Biomarkers of ovarian reserve as predictors of reproductive potential. Semin Reprod Med. 2013;31:437–42.
19. Randolph JF, Sowers M, Bondarenko IV, Harlow SD, Lubosky JL, Little RJ. Change in estradiol and follicle-stimulating hormone across the early menopausal transition: effects of ethnicity and age. J Clin Endocrinol Metab. 2009;89:347–83.
20. van Rooij IA, Broekmans FJM, Te Velde ER, Fauser BCJM. Anti-mullerian hormone levels best reflect the reproductive decline with age and reproductive function in female Sprague-Dawley rats. J Toxicol Sci. 2000;25:701–71.
21. van Rooij IA, Broekmans FJM, van Hoof MH, de Koning CH, Tonch N, Lambalk CB. Predictive value of basal follicle-stimulating hormone concentrations in a general subfertility population. Fertil Steril. 2004;81:601–6.
22. van Rooij IA, Broekmans FJM, Scheffer GJ, Looman CWN, Habbema JD, de Jong FH, Fauser BCJM, Themmen APN, Te Velde ER. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002;17:3065–71.
23. Broer SL, Broekmans FJM, Laven JSE, Fauser BCJM. Anti-Mullerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update. 2014;20:688–701.
24. van Rooij IA, Tonkelaar J, Broekmans FJM, Looman CWJ, Scheffer GJ, de Jong FH, Themmen AP. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002;17:3065–71.
25. van Rooij IA, Tonkelaar J, Broekmans FJM, Looman CWJ, Scheffer GJ, de Jong FH, Themmen AP. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002;17:3065–71.
26. van Rooij IA, Broekmans FJM, Te Velde ER, Fauser BC, Bancsi LF, de Jong FH, Themmen AP. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002;17:3065–71.
27. van Rooij IA, Broekmans FJM, Te Velde ER, Fauser BC, Bancsi LF, de Jong FH, Themmen AP. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002;17:3065–71.
30. Takehara Y, Yabuuchi A, Eze K, Kuroda T, Yamadera R. The restorative effects of adipose-derived mesenchymal stem cells on damaged ovarian function. Lab Invest. 2012;92:181–93.
31. Fu X, He Y, Xie C, Liu W. Bone marrow mesenchymal stem cell transplantation improves ovarian function and structure in rats with chemotherapy-induced ovarian damage. Cytotherapy. 2008;10:353–63.
32. Tatone C, Amicarelli F, Carbone MC, Monteleone P, Caserta D, Marci R, Artini PG, Piomboni P, Focarelli R. Cellular and molecular aspects of ovarian follicle ageing. Hum Reprod Update. 2008;14:131–42.
33. Shimizu T, Jiang JY, Sasada H, Sato E. Changes of Messenger RNA expression of angiogenic factors and related receptors during follicular development in live rats. Biol Reprod. 2002;67:1946–52.
34. Lam PM, Haines C. Vascular endothelial growth factor plays more than an angiogenic role in the female reproductive system. Fertil Steril. 2005;84:1775–8.
35. Ng EH, Chan CC, Yeung WS, Ho PC. Effect of age on ovarian stromal flow measured by three-dimensional ultrasound with power Doppler in Chinese women with proven fertility. Hum Reprod. 2004;19:2132–7.
36. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–9.
37. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983–5.
38. Danforth DR, Arbogast LK, Ghosh S, Dickerman A, Rofigha R, Friedman CI. Vascular endothelial growth factor stimulates preantral follicle growth in the rat ovary. Biol Reprod. 2002;68:1736–41.
39. Shimizu T, Jiang JY, Iijima K, Miyabayashi K, Ogawa Y, Sasada H, Sato E. Induction of follicular development by direct single injection of vascular endothelial growth factor gene fragments into the ovary of miniature gilts. Biol Reprod. 2003;69:1388–93.
40. Wulf C, Wilson H, Wiegand SJ, Rudge JS, Fraser HM. Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor trap (R1R2). Endocrinology. 2002;143:2797–807.
41. Iijima K, Jiang JY, Shimizu T, Sasada H, Sato E. Acceleration of follicular development by administration of vascular endothelial growth factor in cycling Female Rats. J Reprod Dev. 2005;51:161–8.
42. Kosaka N, Sudo N, Miyamoto A, Shimizu T. Vascular endothelial growth factor (VEGF) suppresses ovarian granulosa cell apoptosis in vitro. Biochem Biophys Res Commun. 2007;363:723–7.
43. Quintana R, Kopczow L, Marconi G, Suelo C, Speranza C, Barañao R. Relationship of ovarian stimulation response with vascular endothelial growth factor and degree of granulosa cell apoptosis. Hum Reprod. 2001;16:1814–8.
44. Gutman G, Barak V, Maslovitz S, Amit A, Lessing JB, Geva E. Regulation of vascular endothelial growth factor-A and its soluble receptor sFlt-1 by luteinizing hormone in vivo: implication for ovarian angiogenesis. Fertil Steril. 2008;89:922–6.
45. Zachow RJ, Weitsman SR, Magoffin DA. Hepatocyte growth factor regulates ovarian theca-interstitial cell differentiation and androgen production. Endocrinology. 1997;138:691–7.
46. Ito M, Harada T, Tanikawa M, Fujii A, Shiota G, Terakawa N. Hepatocyte growth factor and stem cell factor involvement in paracrine interplays of theca and granulosa cells in the human ovary. Fertil Steril. 2001;75:973–9.
47. Uzumcu M, Pan Z, Chu Y, Kuhn PE, Zachow R. Immunolocalization of the hepatocyte growth factor (HGF) system in the rat ovary and the anti-apoptotic effect of HGF in rat ovarian granulosa cells in vitro. Reproduction. 2006;132:291–9.
48. Oliver JE, Atman TJ, Powell JF, Wilson CA, Clayton RN. Insulin-like growth factor I gene expression in the rat ovary is confined to the granulosa cells of developing follicles. Endocrinology. 1989;124:2671–9.
49. Kadakia R, Arastoo JA, Bondy C, Zhou J. Granulosa cell proliferation is impaired in the IGF1 null ovary. Growth Horm IGF Res. 2001;11:220–4.
50. Takekati T, Yamagata Y, Takasaki A, Matsuoka A, Tamura H, Sugino N. Effects of growth hormone and insulin-like growth factor 1 on progesterone production in human luteinized granulosa cells. Fertil Steril. 2008;90:744–8.
51. Zhou J, Kumar TR, Matzuk MM, Bondy C. Insulin-like growth factor I regulates gonadotropin responsiveness in the murine ovary. Mol Endocrinol. 1997;11:1924–33.
52. Klein NA, Battaglia DE, Miller PB, Branigan EF, Giudice LC, Soules MR. Ovarian follicular development and the follicular fluid hormones and growth factors in normal women of advanced reproductive age. J Clin Endocrinol Metab. 1996;81:1946–51.